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Polybromo-1 (PBRM1) is an important tumor suppressor in kidney cancer.
It contains six tandem bromodomains (BDs), which are specialized structures
that recognize acetyl-lysine residues. While BD2 has been found to bind
acetylated histone H3 lysine 14 (H3K14ac), it is not known whether other
BDs collaborate with BD2 to generate strong binding to H3K14ac, and the
importance of H3K14ac recognition for the molecular and tumor suppressor
function of PBRM1 is also unknown. We discovered that full-length
PBRM1, but not its individual BDs, strongly binds H3K14ac. BDs 2, 4, and
5 were found to collaborate to facilitate strong binding to H3K14ac. Quanti-
tative measurement of the interactions between purified BD proteins and
H3K14ac or nonacetylated peptides confirmed the tight and specific associa-
tion of the former. Interestingly, while the structural integrity of BD4 was
found to be required for H3K14ac recognition, the conserved acetyl-lysine
binding site of BD4 was not. Furthermore, simultaneous point mutations in
BDs 2, 4, and 5 prevented recognition of H3K14ac, altered promoter binding
and gene expression, and caused PBRM1 to relocalize to the cytoplasm. In
contrast, tumor-derived point mutations in BD2 alone lowered PBRM1’s
affinity to H3K14ac and also disrupted promoter binding and gene expres-
sion without altering cellular localization. Finally, overexpression of PBRM1
variants containing point mutations in BDs 2, 4, and 5 or BD2 alone failed
to suppress tumor growth in a xenograft model. Taken together, our study
demonstrates that BDs 2, 4, and 5 of PBRM1 collaborate to generate high
affinity to H3K14ac and tether PBRM1 to chromatin. Mutations in BD2
alone weaken these interactions, and this is sufficient to abolish its molecular
and tumor suppressor functions.
Abbreviations
3m, N263A-DLF>AAA-N739A mutations; BD2*, N263A mutation; BD2IFD, in-frame deletion of N263; BD4*, DLF>AAA mutation; BD5*,
N739A mutation; BD, bromodomain; BLI, biolayer interferometry; ccRCC, clear cell renal cell carcinoma; CTLA-4, cytotoxic T lymphocyte-
associated 4; H3K14ac, acetylated histone H3 lysine 14; HIF, hypoxia-inducible factor; mRCC, metastatic renal cell carcinoma; PBAF,
polybromo-1-associated BRG1 or BRM-associated factor; PBRM1, polybromo-1; PD-1, programmed death 1; PD-L1, programmed death
ligand 1.
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1. Introduction
Approximately 75% of the renal cell carcinomas are of
the clear cell type (ccRCC). Among them, 70–80% of
sporadic ccRCC tumors harbor biallelic inactivation of
VHL (Linehan et al., 2004). pVHL, the protein pro-
duct of the VHL tumor suppressor gene, is a compo-
nent of an E3 ubiquitin ligase complex. This complex
promotes the poly-ubiquitylation and proteasomal
degradation of the a subunits of the heterodimeric
transcription factor hypoxia-inducible factor (HIF).
When pVHL is inactivated by various mechanisms in
ccRCC, HIF becomes constitutively activated and
turns on the hypoxia response transcriptome. This sub-
sequently drives tumorigenesis and growth of ccRCC
tumors (Kaelin, 2005).
Most solid tumors harbor multiple driver muta-
tions in cancer genes to achieve the hallmarks of
cancer (Hanahan and Weinberg, 2011; Vogelstein
et al., 2013). Forty-one percent of ccRCC tumors
have inactivating mutations in the PBRM1 gene,
and they occur throughout the coding sequence
(Varela et al., 2011). The encoded polybromo-1
(PBRM1) protein is a specificity subunit of the
PBRM1-associated BRG1 or BRM-associated factor
(PBAF) chromatin-remodeling complex (Varela et al.,
2011). The PBAF complex utilizes the energy of
ATP hydrolysis to regulate DNA accessibility by
inserting, removing, or sliding nucleosomes (Harg-
reaves and Crabtree, 2011). The high mutation rate
of PBRM1 in ccRCC has been confirmed by multi-
ple studies (Cancer Genome Atlas Research Net-
work, 2013; Dalgliesh et al., 2010; Guo et al., 2012;
Pena-Llopis et al., 2012; Sato et al., 2013). Muta-
tions in other genes such as BAP1, SETD2,
KDM5C/JARID1C, PTEN, and UTX have also been
identified, but their mutation rates are much lower
than that of PBRM1 (Liao et al., 2015).
PBRM1 is a key tumor suppressor in ccRCC. Its
mutations are predominantly loss-of-function muta-
tions. Suppression of PBRM1 leads to changes in
pathways regulating chromosome instability and cell
proliferation (Varela et al., 2011). Genomic sequencing
of multiple foci of ccRCC tumors has revealed that
the majority of PBRM1 mutations occur early in
tumorigenesis, while mutations in the other secondary
tumor suppressor genes occur later during tumor
development (Gerlinger et al., 2012, 2014). A PBRM1
germline mutation was recently reported to predispose
patients to ccRCC (Benusiglio et al., 2015). PBRM1-
deficient cancer cells exhibit a weakened HIF tran-
scriptional signature (Gao et al., 2017). In mice,
kidney-specific deletion of either Vhl or Pbrm1 does
not lead to ccRCC, but their combined loss does (Gu
et al., 2017; Nargund et al., 2017). Thus, PBRM1
restrains HIF’s tumor-promoting activity.
Since 2005, vascular endothelial growth factor recep-
tor tyrosine kinase inhibitors have been the cornerstone
of therapy for metastatic renal cell carcinoma (mRCC)
(Choueiri and Motzer, 2017; Mihaly et al., 2012).
Recently, however, immunotherapy checkpoint inhibi-
tors that target programmed death 1 (PD-1), pro-
grammed death ligand 1 (PD-L1), and cytotoxic T
lymphocyte-associated 4 (CTLA-4) have gained trac-
tion in mRCC. Indeed, RCC experts are declaring this
combination the new standard of care in the treatment
of mRCC (Chustecka, 2017; Rini, 2017). Loss-of-func-
tion mutations of PBRM1 were recently discovered to
be associated with response to checkpoint inhibition
therapies in ccRCC patients treated with anti-PD-1
alone or in combination with anti-CTLA-4 therapies
(Miao et al., 2018). In addition, PBRM1 mutations
were found to enhance T-cell-mediated killing of tumor
cells in an unbiased, high-throughput screen in a mela-
noma model (Pan et al., 2018). Thus, mutation of
PBRM1 is a biomarker for immunotherapy response.
PBRM1 contains six tandem bromodomains (BDs),
BD1–6, from the N terminus to the middle of the pro-
tein. BDs are small domains with specific affinity for N-
e-lysine acetylation on histones and other proteins
(Dhalluin et al., 1999; Owen et al., 2000). However, it is
not clear why PBRM1 contains so many BDs while
most other BD-containing proteins have only one or
two BDs. As PBRM1 is a specificity subunit of PBAF,
it is hypothesized that it binds to lysine-acetylated his-
tone tails. Previous analyses revealed that BD2 prefer-
entially recognizes acetylated lysine 14 of histone H3
(H3K14ac) and potentially other acetylation sites on
histone H3 (Chandrasekaran and Thompson, 2007;
Charlop-Powers et al., 2010; Thompson, 2009).
Recently, Porter and Dykhuizen (2017) confirmed that
while BD2 is critical for H3K14ac binding, mutation of
BD2 only moderately reduced PBRM1’s binding to
H3K14ac and its association with chromatin. These
findings prompted the authors to speculate that the
other BDs bind additional acetylated histone sites to
ensure tight chromatin association (Porter and Dykhui-
zen, 2017). Slaughter et al. (2018) confirmed the binding
to H3K14ac by BD2 BD4 and showed that neighboring
BDs variably influence nucleosome interactions and cel-
lular function. However, it is still not clear how critical
H3K14ac recognition is to PBRM1’s association with
the chromatin and how mutant PBRM1 impacts tumor
growth in a mouse model.
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In this study, we discovered that BDs 2, 4, and 5 col-
laborate to generate high affinity binding to H3K14ac.
Simultaneous mutations in the involved BDs were
found to completely abolish H3K14ac recognition,
causing PBRM1 to detach from chromatin and relocal-
ize to the cytoplasm. In addition, tumor-derived muta-
tions in BD2 resulted in reduced recognition of
H3K14ac by PBRM1. Although these mutations failed
to significantly change PBRM1’s binding to chromatin,
they significantly impaired PBRM1’s ability to bind to
promoters and regulate gene expression and severely
crippled PBRM1’s tumor suppressor function. Alto-
gether, our findings suggest that BDs 2, 4, and 5 play a
central role in PBRM1 molecular and biological func-
tions by mediating high-affinity recognition of
H3K14ac.
2. Materials and methods
2.1. Cell culture
HEK293T, HeLa, and 786-O cells were purchased
from American Type Culture Collection and cultured
in Dulbecco’s modified Eagle’s medium supplemented
with 10% FBS. The cell lines were maintained in incu-
bators at 37 °C with 5% CO2.
2.2. Protein expression and purification
Polybromo-1 constructs consisting of BD2, BD4,
BD234, and BD245 were subcloned into pGST parallel
expression vectors (Sheffield et al., 1999) individually
expressed in Escherichia coli strain BL21, purified over
a GST column (GE Healthcare, Pittsburgh, PA, USA;
Catalog #17-5130-01), eluted with 10 mM reduced glu-
tathione, and dialyzed against 2 L of dialysis buffer
(25 mM Tris/HCl, 500 mM NaCl, pH 8.0) to remove
glutathione. The purified proteins were incubated with
100 units of rTEV (Invitrogen, Carlsbad, CA, USA;
Catalog #10127-017) for 36 hr at 4 °C. The GST pro-
tein and rTEV were removed by passing the purified
proteins over a GST column, and the flow-through
was collected for biolayer interferometry (BLI).
2.3. Biolayer interferometry (BLI)
Histone H3 binding was measured using BLI using a
ForteBio Octet Red instrument (San Jose, CA, USA).
The assay buffer consisted of 20 mM Tris (pH 7.5),
300 mM NaCl, 1 mM tris(2-carboxyethyl)phosphine,
1 lM ZnCl2, 10% glycerol, and 0.5 mgmL1 bovine
serum albumin. BD2, BD4, BD234, and BD245 pro-
teins were prepared at a concentration of 1 or 2 lM,
and the biotin-labeled H3 peptide was prepared at a
concentration of 25 nM. Biotinylated H3 peptide was
immobilized onto streptavidin-coated sensors (Forte-
Bio) until a threshold signal of 0.4 nm was reached.
BD2, BD4, BD234, and BD245 were allowed to associ-
ate with the ligand-bound sensor for 2000 s followed
by dissociation with assay buffer for 2000 s. All steps
were performed at 25 °C with sensors dipped into
200 lL of sample and stirred at 100 g. Reference sen-
sors (without H3 peptide) were used for each variant
tested to correct for background binding and baseline
drift. Data were processed using the FORTEBIO DATA
ANALYSIS PROGRAM (version 6.4) utilizing reference sub-
traction and Savitzky-Golay filtering. Data were plot-
ted using PRISMGRAPH (Graphpad, San Diego, CA,
USA).
2.4. Plasmids
Full-length PBRM1 cDNA was generated by reverse
transcription–PCR from 786-O cells and cloned into
3XFlag-CMV10 (Sigma, St. Louis, MO, USA) and
pLNCX-GFP vectors (gift from X. Wei (Wang et al.,
2014)). Internal deletion, truncation, and point muta-
tions were made with PCR and the QuikChange Site-
Direct Mutagenesis kit (Agilent Technologies, Santa
Clara, CA, USA; Catalog #200523) and verified by
DNA sequencing. PBRM1 lentiviral shRNA vectors
were purchased from Sigma. The sequences were
PBRM1-sh94: CCGGAGTCTTTGATCTACAAA;
PBRM1-sh890: CCGGAATGCCAGGCACTATA.
2.5. Peptide pull-down, immunoblotting, mono-
nucleosome pull-down
Biotinylated histone H3 peptides were synthesized by
Anaspec (Fremont, CA, USA) and contained residues
1–21 of histone H3 (ARTKQTARKSTGGKAPRKQ
LT). Overexpressed Flag-PBRM1 in HEK293T cells
or endogenous PBRM1 from 786-O cells were
extracted with high salt buffer (containing 0.42 M
NaCl). The samples were mixed with unmodified or
modified biotinylated histone H3 peptides and incu-
bated at 4 °C for 1 hr, followed by addition of strepta-
vidin beads (Pierce Biotechnology, Waltham, MA,
USA; Catalog #20347) and incubation at 4 °C for
1 hr. The bound materials were washed three times
with NETN buffer (100 mM NaCl, 20 mM Tris/Cl pH
8.0, 0.5 mM EDTA, 0.5% (v/v) Nonidet P-40) and
examined by western blots. Cell lysates or peptide
pull-down products were loaded and resolved by SDS/
PAGE. After electrophoresis, proteins were transferred
to nitrocellulose membranes. The membranes were
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blocked at room temperature for 1 hr, then incubated
with appropriate primary antibodies overnight at 4 °C,
and with HRP-conjugated secondary antibody (Invit-
rogen, Catalog #31460 for rabbit and #31430 for
mouse) at room temperature for 1–3 hr. The blots
were developed using ImageQuant LAS 4000 (GE
Healthcare Life Sciences) with HyGLOTM Chemilumi-
nescent HRP Detection Reagent (Denville Scientific,
Swedesboro, NJ, USA; Catalog #E2500). For whole
cell lysates, the cells were solubilized with 1% SDS,
sonicated, and then subjected to SDS/PAGE analysis.
For peptide pull-down of GST-BD fusion proteins,
purified and eluted GST-BD2, GST-BD4, GST-BD12,
GST-BD23, GST-BD34, GST-BD45, and GST-BD245
were incubated with H3 and H3K14ac peptides for
1 hr, followed by incubation with streptavidin beads
for another hr, and then, the beads were washed and
boiled before western blot analysis. The intensity of
the protein bands on the western blot images from
three independent experiments was measured with
NIH IMAGEJ software (Bethesda, MD, USA). The
ratios of H3K14ac peptide-associated bands over the
H3 peptide-associated bands were calculated and plot-
ted, and the P values were calculated with two-tailed
Student’s t-test.
Mono-nucleosome pull-down with GST-BD fusion
protein was performed as previously described (Slaugh-
ter et al., 2018). Briefly, 3 lg purified HeLa mono-
nucleosome (EpiCypher, Durham, NC, USA; Catalog
#16-0009) was incubated with 10 lL bed volume of 300
pmoles pre-immobilized GST-BD fusion protein bound
to glutathione agarose. The assay was performed in
binding buffer (19 PBS, 0.1% NP-40, 0.5% BSA) for
2 h at 4 °C. Beads were washed with binding buffer
and boiled with 29 SDS buffer before western blot
analysis.
Antibodies used include Flag, Sigma M2 F1804;
PBRM1, Bethyl A301-591A; Vinculin, Santa Cruz
Biotechnology sc-5573, Dallas, TX, USA; IKKa,
Santa Cruz Biotechnology sc-7182; IKKc, Santa Cruz
Biotechnology sc-8032; Topo IIb, Santa Cruz Biotech-
nology sc-365421; GST, Cell Signaling Technology,
#2625 (Danvers, MA, USA). H3K14ac, GeneTex (Zee-
land, MI, USA) (GTX88008); GST, Cell Signaling
Technology (2625); histone H3, Bethyl A300-823A
(Montgomery, Texas, USA). For the right panel of
Fig. 2A, the PBRM1 antibody was generated with
GST-BD23 fusion protein in rabbits.
2.6. Cellular fractionation
HeLa cells were transfected with WT and mutant
PBRM1, and, after 36 hr, the cells were scraped and
centrifuged for 5 min at 100 g. Cell pellets were resus-
pended in 500 lL hypotonic buffer (10 mM Tris/HCl,
pH 8.0, 1.5 mM MgCl2, 10 mM KCl and protease inhi-
bitor cocktail [Pierce, Catalog #88666]), incubated on
ice for 15 min, then vortexed for 10 s after adding
25 lL Triton X-100. After centrifuging for 30 s at 17
800 g, the supernatants were collected as the cytoplas-
mic fraction. The pellets were resuspended in 100 lL
hypertonic buffer (20 mM Tris/HCl pH 8.0, 420 mM
KCl, 1.5 mM MgCl2, 20% [v/v] glycerol and protease
inhibitor cocktail) and vortexed for 10 s. Pellets were
incubated on ice for 40 min and vortexed for 15 s
every 10 min. Supernatants were collected as the
nuclear fraction after centrifugation at 17 800 g for
10 min. The remaining pellets were sonicated with 1%
SDS for 3 9 10 s (10 s on/10 s off) using a probe son-
icator, and then, the chromatin part was obtained after
centrifuging at 17 800 g for 10 min.
2.7. The generation of 786-O PBRM1 knockout
clones and re-introduction of wild-type or
mutant PBRM1
sgRNAs (PBRM1-gRNA-F: CACCGTGGCAACCTG
GTTCACCAT, PBRM1-gRNA-R: AAACATGGTGA
ACCAGGTTGCCC) were designed using Optimized
CRISPR Design (crispr.mit.edu) and cloned into
pSpCas9n(BB)-2A-Puro (PX462) V2.0 as previously
described (Ran et al., 2013). 786-O cells were trans-
fected with PX462-sgPBRM1, and, after 36 hr, cells
were selected with puromycin (2.0 lgmL1) for
3 days. Selected cells were then diluted 1 : 100 and
transferred into 15-cm plates. After ~ 10 days, the sin-
gle colonies were isolated using cloning cylinders and
transferred into 24-well plates. After about 2 weeks,
cells were collected for western blot analysis to assess
level of PBRM1 knockout.
The full-length cDNAs of human PBRM1, PBRM1
in-frame deletion of N263 (BD2IFD) mutant, and
PBRM1 3m mutant was cloned into pLNCX-GFP vec-
tor plasmid. The constructs were transfected into
AmphoPack-293 Cell Line (Clontech, Mountain View,
CA, USA; Catalog #631505) to generate retrovirus, and
then, 786-O PBRM1 knockdown cells were transduced
to stably express wild-type or mutant PBRM1. Tumor-
derived PBRM1 mutations were described in Table 1.
2.8. Immunofluorescence
HeLa cells were transfected with wild-type Flag-
PBRM1 or Flag-PBRM1–3m and split into eight-well
chamber slides 1 day after transfection. The next day,
the cells were fixed in 4% paraformaldehyde for
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10 min and permeabilized with 0.5% Triton X-100 for
15 min, followed by three washes with PBS. The cells
were blocked with 5% bovine serum albumin for
60 min and incubated with primary anti-Flag antibody
(Invitrogen, Catalog #MA1-91878) overnight at 4 °C.
The next day, the cells were washed three times with
PBS and incubated with fluorescent secondary anti-
bodies (Santa Cruz Biotechnology, sc-2010) for 1 hr.
Nuclei were stained using DAPI (Invitrogen, Catalog
#D1306). Labeled cells were observed using a green
(488 nm) laser under a confocal microscope (NikonC1
Plus laser; Nikon, Melville, NY, USA) to detect
PBRM1 subcellular localization.
2.9. Quantitative real-time PCR
Total RNA was extracted from cells using the RNeasy
Plus Mini Kit (Qiagen, Venlo, the Netherlands; Cata-
log #74136) according to the manufacturer’s instruc-
tions. RNA concentration was determined using the
NanoDrop ND-1000 system (Thermo Fisher, Wal-
tham, MA, USA). Total RNA (1 lg) was reverse-tran-
scribed using the First Strand cDNA Synthesis Kit
(OriGene, Rockville, MD, USA; Catalog #NP100042).
Quantitative real-time PCR was performed using the
LightCycler 480 (Roche, Basel, Switzerland). The pri-
mers used for real-time PCR are listed in Table 2.
GAPDH was used as an internal control.
2.10. ChIP
ChIP assays were performed using the Pierce Agarose
ChIP Kit (Thermo Scientific, Waltham, MA, USA;
Catalog #26156) according to the manufacturer’s
instructions. Briefly, samples were cross-linked with
paraformaldehyde (final concentration 1%) and incu-
bated at room temperature for 10 min. The cross-link-
ing reaction was halted with glycine (final
concentration 125 mM) and incubated for 5 min at
room temperature. Cells were washed twice with cold
19 PBS and detached by scraping. Cells pellets were
suspended in Lysis Buffer 1 containing protease inhibi-
tors and incubated on ice for 10 min. Nuclei were
resuspended in 100 lL MNase digestion buffer contain-
ing 0.25 lL micrococcal nuclease (10 UlL1) and
incubated at 37 °C for 15 min. The reaction was
stopped with 10 lL MNase Stop Solution. Nuclei were
pelleted by centrifugation at 9000 g for 5 min, then
resuspended in 50 lL lysis Buffer 2 containing pro-
tease/phosphatase inhibitors, and incubated on ice for
15 min. The supernatant, containing the digested chro-
matin, was collected after centrifuging at 9000 g for
5 min. Samples were diluted in 19 IP dilution buffer
and incubated with PBRM1 antibody (Millipore, Bur-
lington, MA, USA; Catalog #ABE70) overnight at
4 °C. Twenty microliter ChIP Grade Protein A/G Plus
Agarose was added into each IP and incubated for 1 hr
at 4 °C. The agarose resins were washed once with IP
Wash Buffer 1, twice with IP Wash Buffer 2 and once
with IP Wash Buffer 3, each with gentle rocking at
4 °C for 5 min. One hundred fifty microliter 19 IP Elu-
tion buffer was added to the washed resin and incu-
bated at 65 °C for 30 min with shaking. Six microliter
of 5 M NaCl and 2 lL of 20 mgmL1 Proteinase K
were added to each sample and incubated at 65 °C for
1.5 h. Then, each eluted IP was washed with DNA col-
umn wash buffer and eluted with 50 lL of DNA Col-
umn Elution buffer. The resulting purified DNA was
Table 1. Tumor-derived mutations.
Position (AA) Mutations (CDS)
Mutations
(amino acid) Mutation ID (COSM) Mutation type Tissue
232 c.694A>C p.T232P COSM52807 Substitution—missense ccRCC
233 c.698T>C p.I233T Substitution—missense Renal cell carcinoma
(OS-RC-2) (Varela et al., 2011)
254 c.761T>C p.L254P COSM52902 Substitution—missense Renal cell carcinoma
256 c.766G>A p.A256T COSM2854199 Substitution—missense Adenocarcinoma
263 c.787_789delAAT p.N263delN COSM1047100 Deletion—in-frame Endometrioid carcinoma
Table 2. Primers for real-time PCR.
GAPDH-F TGCACCACCAACTGCTTAGC
GAPDH-R GGCATGGACTGTGGTCATGAG
OAS1-F CATCTGTGGGTTCCTGAAGG
OAS1-R GAGAGGACTGAGGAAGACAAC
IFI44L-F GAGCACAGAAATAGGCTTCTAGC
IFI44L-R TGGTATCAGACCCCACTACGG
ARPC4-F TCAGTCAATGCCCGTG
ARPC4-R CTCCAGGACGCCTTCG
PBRM1-F GTGTGATGAACCAAGGAGTGGC
PBRM1-R GATATGGAGGTGGTGCCTGCTG
5Molecular Oncology (2019) ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
L. Liao et al. Bromodomains collaborate to strongly bind H3K14ac
used in real-time PCR detection using the primers listed
in Table 3. GAPDH was used as an internal control.
2.11. Nude mice subcutaneous xenograft assays
The recommendations in the Guide for the Care and
Use of Laboratory Animals of the National Institutes
of Health were strictly followed to perform all animal
experiments. Protocol (01462-935A) was approved by
a Thomas Jefferson University Animal Care and Use
Committee and protocol 2015-11286 approved by the
IACUC of Yale University. Subcutaneous xenograft
assays in nude mice were performed as previously
described (Zhang et al., 2013). 786-O cells at 70–80%
confluency were trypsinized and washed twice with ice-
cold PBS. 107 cells in 100 lL PBS were injected subcu-
taneously into one flank of a nude mouse, and the
same number of cells of another cell line was injected
into the other flank of the same mouse. The mice were
sacrificed 6–10 weeks later, and tumors were excised
and weighed.
2.12. Statistical analysis
Statistical significance was determined by the two-
tailed unpaired Student’s t-test. Tumor weights were
assessed in the one-way ANOVA test using GRAPH-
PAD PRISM v7.0 (San Diego, CA, USA). In all fig-
ures, statistical significance is represented as
mean  SEM, and a P-value ≤ 0.05 was considered
statistically significant. *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001, ****P ≤ 0.0001.
2.13. Data accessibility
All data are included in the manuscript. All the mate-
rials are available upon request.
3. Results
3.1. Full-length PBRM1 has strong and specific
binding to H3K14ac
We first examined the binding of full-length PBRM1
to acetylated histone H3 peptides. Nuclear lysates
from HEK293 cells were incubated with biotinylated
histone H3 peptides that were nonmodified, methy-
lated at K4, or acetylated at K4, K9, K14, K18, K23,
K27, or K36. Both exogenous and endogenous full-
length PBRM1 displayed strong binding to the
H3K14ac peptide but not to the H3 peptides acety-
lated on other lysine residues (Fig. 1A). Additionally,
PBRM1 did not bind to the nonmodified or K4
trimethylated H3 peptides (Fig. 1). Our results suggest
that PBRM1 specifically interacts with H3K14ac.
3.2. Bromodomains 2, 4, and 5 collaborate to
strongly bind H3K14ac
We next investigated which PBRM1 BD(s) mediate
recognition of H3K14ac. Flag-tagged constructs con-
taining either full-length PBRM1 or individual BDs
plus adjacent sequences on both ends were expressed
in HEK293 cells. Nuclear lysates were incubated with
biotinylated H3 peptides that were nonmodified or
acetylated on K14, K27, or K36. Full-length Flag-
PBRM1 behaved as expected showing robust binding
to the H3K14ac peptide. However, while BD3 and
BD4 showed modest binding to the peptides, none of
the individual BD constructs displayed the same level
of binding toward H3K14ac compared to full-length
PBRM1 (Fig. 1B), suggesting that cooperation
between multiple BDs may be required for high affi-
nity binding to H3K14ac. To address this possibility,
PBRM1 constructs harboring deletions of the BDs
Table 3. Promoter-specific primers for ChIP.
ZNF395-F CAAGTTTGGCTCCGGGCTGC
ZNF395-R CCTGACCGAGTGGTGACCC
UBE2L6-F CACGGAGCTGCGTCTGTACA
UBE2L6-R CGGCCGCACCGGGAGCTCTC
IGFBP3-F GAGCACTGCGGCTGGGCGCT
IGFBP3-R GGCACGCTGCTTGGCAGGCT
GAPDH-F TGAGCCCGCAGCCTCCCGCT
GAPDH-R CCGGGTTTCTCTCCGCCCGT
Fig. 1. BDs 2, 4, and 5 collaborate to strongly bind H3K14ac. (A) Flag-PBRM1 was expressed in HEK293T cells. The EBC cell lysates were
pulled down with indicated biotinylated peptides and analyzed with indicated antibodies (top). HEK293 lysates were treated the same way
to examine the interaction between endogenous PBRM1 and biotinylated histone H3 peptides (bottom). (B) Full-length PBRM1 or individual
BDs of PBRM1 were expressed in HEK293T cells. Their binding to different biotinylated peptides was analyzed as described in (A). (C) Full-
length PBRM1 or PBRM1 with BDs sequentially truncated was expressed in HEK293T cells and analyzed as described above. (D) Full-length
PBRM1 or different combinations of BDs of PBRM1 were expressed in HEK293T cells and analyzed as described above. (E) The aligned
protein sequences of BD 2 from different species, and the conserved YN residues that are critical for acetyl-lysine recognition were labeled
with a box. (F) Full-length PBRM1 or different combinations of BDs of PBRM1, in the presence or absence of indicated mutations, were
expressed in HEK293T cells and analyzed as described above. BD2* indicates N263A point mutation in BD2.
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were generated, beginning with deletion of BD1 at the
N terminus and containing successive deletions of each
BD (DBD1–6, Fig. 1C). Peptide pull-down assays were
conducted with nonmodified or acetylated H3 pep-
tides. Flag-DBD6, which lacks all the BDs of PBRM1,
showed negligible binding to H3K14ac. While deletion
of BD1 (Flag-DBD1, row 2) did not affect H3K14ac
binding in this assay, deletion of BDs 1 and 2 (Flag-
DBD2, row 3) greatly reduced the binding of PBRM1
to H3K14ac. Deletion of BDs 1–4 (Flag-DBD4, row
5) further reduced binding to H3K14ac compared to
deletion of BDs 1–3 (Flag-DBD3, row 4). Further
deletion of BD5 (Flag-DBD5, row 6) completely abol-
ished binding of H3K14ac versus the nonacetylated
H3 peptide (Fig. 1C), suggesting that BDs 2, 4, and 5
contribute to H3K14ac binding.
Since the sequential deletion of BDs only reduced
PBRM1’s affinity to H3K14ac gradually, we used
different combinations of BDs 1–4 to critically exam-
ine their contributions to H3K14ac binding. The
combination of BDs 2, 3, and 4 (Flag-BD234,
Fig. 1D, row 2) showed a similar level of binding
toward H3K14ac as full-length PBRM1 (row 1),
while the construct containing BDs 1, 2, and 3
(Flag-BD123) showed no affinity to H3K14ac
(Fig. 1D, row 3), indicating that BD4 is important
for the interaction. Additionally, the construct con-
taining BDs 2 and 4 (Flag-BD24, row 6), but not 2
and 3 or 3 and 4 (Flag-BD23 and Flag-BD34, rows
4 and 5 respectively), showed high affinity to
H3K14ac (Fig. 1D). Altogether, results show that the
combination of BDs 2 and 4 of PBRM1 creates high
affinity to H3K14ac, while BDs 1 and 3 contribute
significantly less to the binding.
The tyrosine-rich binding pocket in BD 2 contains
a YN sequence that is highly conserved through evo-
lution (Fig. 1E, top panel). The asparagine at posi-
tion 263 (N263) had been previously found to be
critical for the recognition of acetyl-lysine by forming
a hydrogen bond with the acetylated lysine on target
proteins (Dhalluin et al., 1999; Owen et al., 2000).
Here, the N263A mutation (denoted as BD2*),
which disrupts the YN motif in BD2, abolished the
enhanced affinity of Flag-BD234-BD2* toward
H3K14ac over the nonacetylated peptide (Fig. 1F,
row 2). BD2* also reduced H3K14ac binding by full-
length PBRM1 in Flag-PBRM1-BD2* (compare rows
3 and 4), but the enhanced binding to H3K14ac over
nonacetylated peptide still persisted, suggesting that
BDs other than BD2 are also critical for the interac-
tion. Confirming the result in Fig. 1D, the addition
of BD1 did not help Flag-BD234-BD2* to bind
H3K14ac (Fig. 1F, row 5). Instead, the addition of
BDs 5 and 6 did (Fig. 1F, row 6). Leaving out BD6
did not alter H3K14ac binding, while in-frame dele-
tion of BD5 in Flag-BD2346-BD2* abolished the
recognition of H3K14ac over nonacetylated peptide
(Fig. 1F, rows 7 and 8). This suggests that BD5
of PBRM1 also makes a critical contribution to
H3K14ac recognition.
3.3. In vitro measurement confirms that BDs 2, 4,
and 5 collectively bind H3K14ac with high affinity
To examine the conclusions made by Flag-BD con-
structs, we generated GST-BD constructs and tested
their binding to histone H3 peptides. GST-BD2 or 4
again showed little binding under the stringent binding
condition. GST-BD12 showed weak binding to
H3K14ac (Fig. 2A row 2 versus 1, 2B), suggesting that
BD1 helps BD2 to bind it, consistent with a previous
report (Porter and Dykhuizen, 2017). BD3 helped
BD2, but not much so for BD4, to bind H3K14ac,
likely by increasing the affinity to the nonacetylated
peptide backbone (Fig. 2A row 3 versus 1 and row 5
versus 4, 2B). BD5 also helped BD4 to bind H3K14ac,
Fig. 2. Quantitative measurement confirms that BD245 work together to create high affinity to H3K14ac. (A) The indicated GST-BD
constructs of PBRM1 were expressed and purified from Escherichia coli, pulled down by the indicated peptides, and immunoblotted with
anti-GST antibody. (B) The bands in (A) were quantified with NIH ImageJ, and the ratios of bands associated with H3K14ac/H3 were
calculated from three experiments. The P-values were calculated using the two-tailed Student’s t-test. *: P < 0.05; **: P < 0.01; ***:
P < 0.001. N.S.: nonsignificant. (C) Top: The indicated GST-BD constructs of PBRM1 were expressed and purified from Escherichia coli.
Similar amount of GST-fusion protein was incubated with 3ug of nucleosome purified from HeLa cells, washed then analyzed with indicated
antibodies. Arrow: the full-length GST-BD12 protein. Bottom: The intensity of the pulled down H3 or H3K14ac bands was determined with
ImageJ from three different experiments, and the ratios of H3/input and H3K14ac/input were calculated and plotted. The error bars
represent standard error of the mean. (D) GST-BD fusion proteins (left) or cleaved and purified BD proteins (right) were pulled down with
indicated peptides and analyzed with western blots. (E) BLI analysis of the interaction between PBRM1 BD proteins and the H3K14ac
peptide. Binding activity was normalized to maximum response and is reported as relative binding. The association phase takes place from
0 to 900 s; the dissociation phase takes place from 901 to 2200 s. (F) Binding parameters of PBRM1 BD constructs and H3 peptide
interactions. Apparent Kd values (K
app
d ) were obtained for the interaction between PBRM1 BD proteins and H3 peptides by fitting BLI data
to a double exponential function. The H3:H3K14ac reports the preference of PBRM1 BD proteins to bind the H3K14ac peptide over the
nonacetylated H3 peptide.
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consistent with the Flag-BD result (Figs 2A row 6 ver-
sus 4, 2B and 1F). BD245 displayed the strongest and
specific binding to H3K14ac compared to other strong
binders (Fig. 2A row 7 versus the rest and 2B). The
conclusions on BD 1 and 3 are somewhat different
from those derived from Flag-BD pull-downs, suggest-
ing that subtle differences can be revealed if the condi-
tion is permissive.
To confirm that our conclusions are not artifacts
created by binding to peptides, we incubated GST-BD
proteins with mono-nucleosome purified from HeLa
cells. GST-BD2, BD4, BD12, or BD45 all pulled down
histone H3 and enriched H3K14ac, but again BD245
showed the strongest binding to histone H3 and
H3K14ac (Fig. 2C top, lane 6 versus the rest). GST-
BD12 had some obvious breakdown products and they
might interfere with binding to the nucleosome. After
quantification, it was found that all BD constructs had
higher ratios of H3K14ac/input over H3/input, sug-
gesting that these constructs demonstrated selective
binding to the modification (Fig. 2C, bottom). The
result suggests that BD245 has the highest affinity to
H3K14ac even when it is present in intact nucleosome.
To confirm the roles of BDs 2, 4, and 5 in recogni-
tion of H3K14ac, we measured the interactions
between histone H3 peptides and purified BD proteins.
GST-fusion proteins of BD2, BD4, BD234, and
BD245 were purified, and their ability to bind biotiny-
lated histone H3 peptides was assessed. The peptide
pull-down assay showed little to no interaction
between GST-BD2 and GST-BD4 with H3K14ac,
while GST-BD234 and GST-BD245 had significantly
higher affinity toward H3K14ac than to the nonacety-
lated H3 peptide (Fig. 2D, left panel). After GST-tag
removal, the BD proteins still retained their previous
characteristics and were used for further analysis
(Fig. S1 and Fig. 2D, right panel).
To validate the detected interactions, we compared
binding among the BD proteins using BLI. Fig-
ure 2E shows the results of the BLI assay measuring
the interaction of a similar concentration of each
BD construct on sensors loaded with biotinylated
histone H3 or H3K14ac peptides. BD2, BD4,
BD234, and BD245 all showed histone H3-dependent
association with sensors, albeit with distinctly differ-
ent binding levels and rates of association. BD245
and BD234 showed distinct preferences for binding
acetylated versus nonacetylated H3K14 peptides with
binding ratios of 12.3 and 6.8, respectively (Fig. 2F).
In contrast, BD2 and BD4 domains showed
little preference for acetylated versus nonacetylated
H3K14 peptides (binding ratios of 1.7 and 1.5,
respectively; Fig. 2F). Little difference in dissociation
rates was observed when bound sensors were incu-
bated in buffer (right side of dotted line in Fig. 2E),
suggesting that the differences in affinity were largely
due to the different rates of association. In addition,
the data for BD245 and BD234 were best fit using a
double exponential rate equation, suggesting that
high affinity may be achieved by real multivalent or
artifactual surface interactions. Given that the trends
in affinities match those observed in peptide pull-
down assays, real multivalent interactions are more
likely. Taken together, quantitative measurements by
BLI confirmed the observation that BDs 2, 4, and 5
contribute to high affinity binding of H3K14ac by
PBRM1.
3.4. Concurrent point mutations in BDs 2, 4, and
5 abolish PBRM1’s recognition of H3K14ac and
alter its subcellular localization
Previous results demonstrated that the conserved YN
residues in BD2 are critical for H3K14ac binding
(Fig. 1E) (Chandrasekaran and Thompson, 2007;
Charlop-Powers et al., 2010; Porter and Dykhuizen,
2017). We next tested whether the conserved YN resi-
dues in BD4 and/or BD5 are also critical for
H3K14ac binding. In addition to the highly conserved
YN motif in BD4 (residues: 600–601), there is a sec-
ond, less-conserved YN motif (residues: 608–609) in
BD4. These motifs are disrupted by the N601A
(YN1) and N609A (YN2) mutations (Fig. 3A). Nei-
ther of the single mutations nor the double mutation
changed the affinity of BD234 toward H3K14ac
(Fig. 3B, rows 3, 4 and 5), suggesting BD4 uses a dif-
ferent mechanism to achieve H3K14ac recognition.
We aligned the amino acid sequences of BDs from
human PBRM1, BRG1, and BRM and identified a
DLF sequence in BD 4, which is highly conserved
among BD4 of PBRM1 from different species and
has similar amino acid residues in different BD
domains (Fig. 3A). We mutated these residues to ala-
nine (DLF>AAA, BD4*) and found that it greatly
reduced binding of BD234 to H3K14ac (Fig. 3B, row
6), indicating that this highly conserved sequence in
BD4 is required for H3K14ac binding. Simultaneous
mutation of the YN motifs in BDs 2 and 5 (N263A
and N739A, BD2* and BD5*) abolished the affinity
of BD2345 toward H3K14ac compared to the N263A
single mutation (Fig. 3C, compare rows 2 and 3),
confirming that the YN motif in BD5 is also critical
for H3K14ac binding. Altogether, results show that
the YN motifs of BDs 2 and 5 as well as the DLF
sequence of BD4 are necessary for H3K14ac recogni-
tion.
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A recent publication suggested that a ccRCC-
derived BD4 N601K mutation could significantly
reduce H3K14ac recognition in GST-BD4 and
BD45 (Slaughter et al., 2018). We compared it with
Y600N601-AA mutant and found that it did signifi-
cantly reduce the binding to H3K14ac in Flag-BD234
(Fig. S2). Thus, this N601K mutation might change
the structure of BD4 while the Y600N601-AA
may not.
After defining the critical binding residues of BDs 2,
4, and 5 with smaller constructs, we investigated how
mutation of these residues affects the binding between
full-length PBRM1 and H3K14ac. The individual
N263A (BD2*), DLF>AAA (BD4*), and N739A
(BD5*) mutations each slightly reduced the affinity
toward H3K14ac (Fig. 3D, rows 2, 3, and 4), while
the N263A-N739A (BD2* and 5*) double mutation
reduced the affinity further (Fig. 3D, row 5). The tri-
ple mutation N263A-DLF>AAA-N739A (3m) com-
pletely abolished the ability of full-length PBRM1 to
bind H3K14ac (Fig. 3D, row 6), indicating that
concurrent mutations within BDs 2, 4, and 5 are nec-
essary and sufficient to prevent specific recognition of
H3K14ac.
Polybromo-1 is a chromatin-associated protein (Por-
ter and Dykhuizen, 2017). To examine the influence of
BD mutations on PBRM1 localization, we transfected
HeLa cells with wild-type, the triple BD mutant, or
the BD2 mutant. Cells were then fractionated into the
cytoplasmic, soluble nuclear, and chromatin-bound
fractions. Wild-type PBRM1 was present in each of
the cellular compartments but was predominantly
localized to the nucleus (Fig. 4A). The triple BD
mutant, which is unable to recognize H3K14ac, accu-
mulated in the cytoplasm, with low levels found in the
soluble nuclear and chromatin-bound fractions
(Fig. 4A). In contrast, PBRM1 with a mutation only
in BD2 had a similar distribution to the wild-type pro-
tein (Fig. 4A). Immunofluorescence confirmed the
findings, as wild-type PBRM1 mainly localized in the
nucleus and the triple BD mutant primarily localized
to the cytoplasm (Fig. 4B and Fig. S3). This analysis
Fig. 3. Concurrent point mutations in BDs 2, 4, and 5 abrogate PBRM1’s recognition of H3K14ac. A) Sequence alignment of the six BDs of
human PBRM1 and the BDs of BRG1 and BRM. *: conserved residues : or.: highly similar amino acids. The residues mutated in B–D were
boxed. (B, C, and D) The indicated PBRM1 constructs were expressed in HEK293T cells, pulled down by the indicated peptides, and
immunoblotted with anti-Flag antibody. The * in the rows indicate point mutations.
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suggests that loss of H3K14ac recognition alters the
subcellular localization of PBRM1.
3.5. Tumor-derived mutations in BD2 result in
loss of H3K14ac binding, loss of promoter
binding, and deregulation of gene expression
It has been reported that ~ 40% of ccRCC harbor
inactivating mutations in PBRM1 (Varela et al., 2011).
Other cancers also have PBRM1 mutations. Many
missense mutations have been found in the BDs. Map-
ping the tumor-derived mutations to the available crys-
tal structures of the PBRM1 BDs 2, 4, and 5
(Filippakopoulos et al., 2010) provides further insight
into the mechanism of how these mutations described
in Table 1 may affect PBRM1 function. Mutation
N263A changes the highly conserved asparagine resi-
due at the C-terminal end of helix aB in BD2
(Fig. 5A), thereby removing a critical hydrogen bond
between the asparagine and the acetyl-lysine moiety,
which often abolishes binding of acetyl-lysine peptides
(Dhalluin et al., 1999). Since I233 belongs to a group
of highly conserved hydrophobic residues in helix aA
that contribute to the stability of the BD core (Filip-
pakopoulos et al., 2010), its mutation to T in BD2
(Fig. 5A) is likely to destabilize the BD fold. Similarly,
mutation of A256 in helix aC to T is predicted to
interfere with the tightly packed hydrophobic core of
BD2 (Fig. 5A), leading to destabilization. While resi-
dues T232 and L254 occur in less-conserved positions
and hence do not seem to adopt a specific structural
role in BDs, their mutations to prolines may interfere
with the BD fold, as prolines introduce kinks into a-
helices. In summary, most tumor-derived mutations in
PBRM1 BD2 structurally and functionally affect
important conserved residues, leading to detrimental
effects either on acetyl-lysine peptide recognition or
BD stability. The DLF segment mutated to AAA in
Fig. 4. Concurrent point mutations in BDs 2, 4, and 5 cause PBRM1 relocalization to the cytoplasm, while mutation in BD2 alone does not.
(A) Wild-type or mutant PBRM1 constructs were transiently expressed in HEK293T cells. The cells were fractionated into cytoplasmic,
soluble nuclear, and chromatin-bound fractions. The lysates were blotted with the indicated antibodies. The blots of IKKc, IKKa, and Topo IIb
indicate the successful separation of cellular compartments. (B) Wild-type or mutant PBRM1 constructs were expressed in HeLa cells.
Immunofluorescence was performed using anti-Flag antibody. The DNA is stained blue with DAPI, while the PBRM1 signal is stained green.
Fig. 5. Tumor-derived mutations mapped onto crystal structures of BDs. (A) Tumor-derived mutations were mapped onto the available
crystal structure of BD2 of PBRM1 (Filippakopoulos et al., 2010). (B) BD4* mutation was mapped onto the available crystal structure of BD4
of PBRM1 (Filippakopoulos et al., 2010). (C) The location of the critical N739 was mapped onto the available crystal structure of BD5 of
PBRM1 (Filippakopoulos et al., 2010).
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BD4 resides in a short helical turn with a highly con-
served phenylalanine (Fig. 5B) that is thought to stabi-
lize the hydrophobic binding pocket through
interactions with helix aC (Filippakopoulos et al.,
2010). N739A also changes the highly conserved aspar-
agine residue at the C-terminal end of helix aB in BD5
(Fig. 5C).
We hypothesized that these tumor-derived mutations
would alter PBRM1’s function through impairing its
ability to recognize H3K14ac. We used site-directed
mutagenesis to introduce tumor-derived mutations
into Flag-BD234. The N263A mutation abolished
H3K14ac recognition in BD234 but only reduced it in
BD2345 (Fig. 3B,C, compare rows 1 and 2), so Flag-
Fig. 6. Tumor-derived mutations in BD2 weaken PBRM1’s recognition of H3K14ac, its ability to regulate gene expression, and its binding to
promoters. (A) Wild-type BD234 of PBRM1 or BD234 carrying tumor-derived mutations were expressed in HEK293T cells. The lysates were
pulled down with the indicated peptides and immunoblotted with anti-Flag antibody. (B) 786-O cells were infected to stably express the
indicated shRNA and/or PBRM1 constructs. The lysates were blotted with indicated antibodies. The relative mRNA expression of (C)
PBRM1, (D) GAS6, (E) OAS1, (F) IFI44L, and (G) ARPC4 over SCR-expressing cells was examined with qRT–PCR in the indicated cells from
two experimental results. (H) PBRM1 constructs or GFP was transiently transfected into 786-O cells with PBRM1 knocked out by CRISPR/
Cas9. Anti-PBRM1 ChIP was performed and the enrichment of promoter sequences for (I) ZNF-395, (J) UBE2L6, or (K) IGFBP3 was
measured by qPCR. The ChIP/input ratio for each promoter from the nontransfected cells was set as 1, and the relative enrichment was
calculated by dividing the ChIP/input ratio from the transfected cells with that from the control cells from two experimental results. The
error bars represent standard error of the mean. The P-values were calculated using the two-tailed Student’s t-test. *: P < 0.05; **:
P < 0.01; ***: P < 0.001; ****: P < 0.0001.
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BD234 is more sensitive to the perturbation of
H3K14ac recognition by mutations in BD2. The
BD2IFD, T232P, and L254P mutations completely
abolished H3K14ac binding (Fig. 6A, rows 2, 3, and
5), while I233T reduced binding and A256T had no
apparent effect (Fig. 6A, rows 4 and 6). These muta-
tions all occur in BD2. These results suggest that many
tumor-derived mutations in PBRM1’s BD2 impair its
ability to recognize H3K14ac, indicating that this
binding event may be critical for its tumor suppressor
function.
Histone lysine acetylation is important during tran-
scription and is generally linked to gene activation
(Wang et al., 2008). We predicted that BD mutations
that disrupted H3K14ac binding would negatively
impact PBRM1’s role in gene expression. We
employed microarray analyses to profile differentially
expressed genes upon PBRM1 shRNA knockdown in
786-O ccRCC cells. Knockdown of PBRM1 led to
upregulation of GAS6 and ARPC4, and downregula-
tion of OAS1 and IFI44L relative to control scrambled
shRNA cells. Re-expression of shRNA-resistant wild-
type PBRM1 or PBRM1 BD mutants (Flag-PBRM1–
3m, Flag-PBRM1-BD2IFD, Flag-PBRM1-T232P) in
PBRM1 knockdown cells restored PBRM1 protein
similar to endogenous levels and increased PBRM1
mRNA levels in 786-O cells (Fig. 6B,C). Expression of
wild-type PBRM1 reversed the effects of PBRM1
knockdown, leading to downregulation of GAS6
(Fig. 6D), upregulation of OAS1 (Fig. 6E) and
IF144L (Fig. 6F), and downregulation of ARPC4
(Fig. 6G). Neither the triple BD mutant nor the BD2
mutants harboring BD2IFD or T232P were able to
rescue the defects in gene expression resulting from
PBRM1 suppression (Fig. 6D–G). Taken together, our
data suggest that BD mutations that weaken H3K14ac
recognition impair the ability of PBRM1 to regulate
gene expression.
We carried out ChIP followed by sequencing to
identify PBRM1 target promoters and detected
ZNF395, UBE2L6, and IGFBP3 promoters among
them. To determine whether the BD mutations affect
chromatin binding by PBRM1, we performed ChIP-
qPCR in 786-O cells with PBRM1 knocked out by
CRISPR/Cas9. GFP, wild-type PBRM1, PBRM1–3m,
and tumor-derived mutants PBRM1-BD2IFD and
PBRM1-T232P were transiently expressed in the cells
(Fig. 6H). After overexpression of wild-type PBRM1,
ChIP with anti-PBRM1 confirmed that PBRM1 bound
to the promoters of ZNF395, UBE2L6, and IGFBP3
(Fig. 6I–K). However, despite equal expression levels
as the wild-type PBRM1, the PBRM1–3m, PBRM1-
BD2IFD, and PBRM1-T232P mutants demonstrated
significantly reduced binding to the promoters
(Fig. 6I–K), suggesting that reduced H3K14ac recogni-
tion is sufficient to impair the recruitment of PBRM1
to select promoters.
3.6. H3K14ac recognition is critical to PBRM1’s
tumor suppressor function
Select BD mutations impaired PBRM1’s ability to rec-
ognize H3K14ac, regulate gene expression, and localize
to promoters. Using mouse xenograft models, we
tested whether the PBRM1 BD mutations abrogate its
tumor suppressor function. We found that 786-O
PBRM1 knockdown cells generated significantly larger
tumors than control cells, consistent with previous
reports suggesting that PBRM1 is a potent tumor sup-
pressor that inhibits tumor growth (Gao et al., 2017).
Re-expression of shRNA-resistant wild-type PBRM1
in the knockdown cells resulted in significantly smaller
tumors than the GFP-expressing control (Fig. 7A,B).
Overexpression of the tumor-derived BD2IFD mutant
or the 3m mutant failed to significantly suppress tumor
growth compared to wild-type PBRM1 (Fig. 7C–F).
These results demonstrate that PBRM1 BD mutants
lose tumor suppression function in mouse xenografts,
suggesting that H3K14ac recognition is key to
PBRM1’s tumor suppressor function in vivo.
4. Discussion
Using mutations in individual BDs in the context of
full-length PBRM1, Porter and Dykhuizen (2017)
found that the multi-BD organization contributed to
PBRM1 association with chromatin. They hypothe-
sized that BD2 binds H3K14ac while other BDs bind
additional acetylation sites on histone tails, and collec-
tively, these interactions generate high affinity to chro-
matin. However, it is not clear whether interactions
between additional histone acetylation sites and the
BDs of PBRM1 play an important role in targeting
PBRM1 to the chromatin.
Our work suggests that H3K14ac is a major acetyla-
tion mark on histone H3 that recruits PBRM1 to
chromatin. Full-length PBRM1 displayed significantly
enhanced affinity toward H3K14ac compared to the
nonacetylated counterpart while the individual BDs
did not. This observation prompted us to hypothesize
that multiple BDs in PBRM1 collaborate to create
high affinity to H3K14ac.
The peptide pull-down assay of PBRM1 in cellular
lysates is semiquantitative in nature. In order to quan-
titatively measure the affinity between H3K14ac and
the BDs of PBRM1, either alone or in combination,
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we produced and purified BD2, BD4, BD234, and
BD245 proteins in E. coli. With these reagents, we suc-
cessfully measured the binding efficiency between the
proteins and the acetylated and nonacetylated H3 pep-
tides. The results unequivocally confirmed that BD245
and BD234 had significantly higher affinity toward
H3K14ac than to its nonacetylated counterpart, while
BD2 and BD4 did not show significant preference
(Fig. 2C). However, the exact molecular mechanism of
this cooperation remains a mystery. One scenario is
that one BD binds to H3K14ac while the other BDs
bind to nearby residues on the same peptide that may
not necessarily include acetylated lysine residues.
Although such BD–peptide interactions may be weak,
they may provide an avidity effect to generate strong
binding. Alternatively, different BDs on one PBRM1
molecule may simultaneously bind to H3K14ac on dif-
ferent molecules that are in close proximity. Since each
nucleosome contains two H3, it is possible that two
adjacent tails with H3K14ac might provide the binding
sites for PBRM1. These hypotheses can be further
tested with in-depth structural analysis with H3K14ac
peptide bound to multi-BD proteins.
Our results are largely consistent with a recent pub-
lication in which BDs 2 and 4 are found to be critical
for H3K14ac recognition and nucleosome binding
(Slaughter et al., 2018), and the neighboring BDs mod-
ulate the interaction with histone H3 peptides.
Fig. 7. H3K14ac recognition is critical to PBRM1’s tumor suppressor function. Xenograft analyses were performed to compare tumor
growth of 786-O cells with PBRM1 stably suppressed by PBRM1-sh94. (A) Representative tumors derived from cells expressing GFP or
shRNA-resistant wild-type PBRM1; (B) quantification of tumor weights in A); C) representative tumors derived from cells expressing shRNA-
resistant wild-type PBRM1 or PBRM1 with N263 in-frame deletion; (D) quantification of tumor weights in (C); (E) representative tumors
derived from cells expressing shRNA-resistant wild-type PBRM1 or PBRM1 with mutations in BDs 2, 4, and 5; (F) quantification of tumor
weights in (E). The error bar depicts standard error of the mean, and P-values were calculated using the two-tailed Student’s t-test. n
indicates the number of mice used in each experiment.
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However, we found that BD245 had the highest affin-
ity to H3K14ac which is critical to anchor PBRM1 in
the nucleus. In addition, more subtle mutation of
Y600N601-AA in BD4 did not affect BD4’s ability to
bind to H3K14ac even though N601K did, suggesting
that N601K mutation might disturb the structure of
BD4 like the DLF-AAA mutation.
Here, we also identified point mutations in BDs 2,
4, and 5 that were critical for H3K14ac recognition.
Interestingly, BD4 is peculiar in that the conserved
N601, a residue that is predicted to be critical to rec-
ognize acetyl-lysine, appears to not be required for
H3K14ac recognition. Instead, the conserved DLF
motif, which is thought to be critical for the structural
integrity of BD4’s acetyl-lysine binding pocket, was
required for H3K14ac recognition. Thus, BD4’s contri-
bution to H3K14ac recognition is likely not based on
its ability to directly bind to acetyl-lysine. It is possible
that BD4 positions or stabilizes BD2 and/or BD5 in a
state that yields high affinity for H3K14ac. With
N263A (BD2*), DLF>AAA (BD4*) and N739A
(BD5*) integrated into full-length PBRM1 (singly or
combined) we found that a point mutation in a single
BD only moderately reduced PBRM1’s binding to
H3K14ac. Only when all three BDs were disrupted
simultaneously was the specific binding completely
abolished. The triple mutant also lost the affinity to
chromatin and relocated to the cytoplasm, while the
single BD2* mutant did not change cellular localiza-
tion (Fig. 4), suggesting that strong H3K14ac recogni-
tion is critical to tether PBRM1 to chromatin.
We further tested the impact of tumor-derived point
mutations in BD2. As expected, most of them abol-
ished H3K14ac binding in the BD234 construct. Map-
ping these mutations onto available crystal structures
of the PBRM1 BDs revealed that these mutations
impact either important structural or functional resi-
dues. Interestingly, the individual point mutants were
nearly as defective as the triple mutant in regulating
gene expression, binding to promoters (Fig. 6B–K),
and suppressing tumor growth (Fig. 7). This suggests
that even though tumor-derived point mutations in the
BDs of PBRM1 might not grossly alter chromatin
association, they are sufficient for the disruption of
PBRM1’s molecular and tumor suppressor functions.
Porter and Dykhuizen (2017) and Slaughter et al.
(2018) used in vitro growth curves of Caki-2 or RCC4
cells re-expressing wild-type or BD mutants as a gauge
of PBRM1’s tumor suppressor function. However, this
might not be an accurate measure. In PBRM1-profi-
cient 786-O cells, deletion or suppression of PBRM1
did not alter cell growth in culture, but it significantly
enhanced tumor growth in vivo (Gao et al., 2017).
Thus, we think that xenograft analysis is a better tool
to assess PBRM1’s tumor suppressor function than
measuring proliferation in cell culture. The knock-in
of Pbrm1 mutants into the mouse genome combined
with Vhl inactivation should be the best physiological
model to evaluate the impact of these mutations.
5. Conclusions
It has long been a puzzle: Why does PBRM1 have six
tandem BDs? Our analysis provides a clear answer to
this question: Individual BDs of PBRM1 does not have
high enough affinity to H3K14ac to allow proper bind-
ing. Instead, BDs 2, 4, and 5 work together to generate
high affinity toward H3K14ac. If this recognition is dis-
rupted by simultaneous mutation of all three BDs,
PBRM1 will relocalize to the cytoplasm. However, a
single point mutation in BD2 alone that reduces
H3K14ac recognition was sufficient to severely impair
PBRM1’s molecular and tumor suppressor functions
despite maintaining chromatin association. So our find-
ings suggest that PBRM1’s molecular and tumor sup-
pressor functions depend on the recognition of
H3K14ac by multiple BDs, and PBRM1 is an impor-
tant reader of H3K14ac, a universal epigenetic marker
of actively transcribing genes. Many tumor-derived
mutations disrupt this recognition, attesting to its
importance. As PBRM1 deficiency has been shown to
boost the efficacy of immune checkpoint drugs in
ccRCC and other cancers (Miao et al., 2018; Pan et al.,
2018), the disruption of H3K14ac recognition by
PBRM1 has the potential to increase the response rate
of immunotherapy and warrants further investigation.
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Fig. S1. The production of purified BD proteins. GST-
BD fusion proteins were induced in E. coli and the
purified proteins were cleaved with TEV protease. The
lysates and proteins were resolved by SDS-PAGE and
stained with coomassie blue. Red arrow: BD proteins.
Green arrow: GST protein.
Fig. S2. N601K mutation in BD4 reduces H3K14ac
binding while Y600N601-AA mutation does not. The
indicated Flag-BD234 constructs were expressed in
HEK293T cells, pulled down by the indicated peptides,
and immunoblotted with anti-Flag antibody.
Fig. S3. Concurrent point mutations in BDs 2, 4 and 5
cause PBRM1 to relocalize to the cytoplasm. Flag-
tagged wild-type or 3m mutant PBRM1 constructs
were expressed in HeLa cells. Immunofluorescence was
performed using anti-Flag antibody. The DNA is
stained blue with DAPI, while the PBRM1 signal is
stained green.
18 Molecular Oncology (2019) ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
Bromodomains collaborate to strongly bind H3K14ac L. Liao et al.
